Article thumbnail

Expression of X-linked Inhibitor of Apoptosis Protein in Neoplastic Thyroid Disorder

By Ji Hye Yim, Jong Ho Yoon, Sun A Kim, Won Gu Kim, Min Ji Jeon, Ji Min Han, Tae Yon Sung, Tae Yong Kim, Won Bae Kim, Suck Joon Hong, Young Kee Shong and Gyungyub Gong

Abstract

X-linked inhibitor of apoptosis protein (XIAP) is associated with tumor genesis, growth, progression and metastasis, and acts by blocking caspase-mediated apoptosis. In the present study, we sought to evaluate the expression patterns of XIAP in various neoplastic thyroid disorders and determine the association between XIAP expression and clinicopathologic factors. Expression of XIAP was evaluated with immunohistochemical staining using monoclonal anti-XIAP in 164 specimens of conventional papillary thyroid carcinoma (PTC) and 53 specimens of other malignant or benign thyroid tumors. XIAP positivity was observed in 128 (78%) of the 164 conventional PTC specimens. Positive rates of XIAP expression in follicular variant PTC, follicular, medullary, poorly differentiated, and anaplastic thyroid carcinoma specimens were 20%, 25%, 38%, 67%, and 38%, respectively. Six nodular hyperplasia specimens were negative and 1 of 7 follicular adenomas (8%) was positive for XIAP. Lateral neck lymph node metastases were more frequent in patients negative for XIAP expression (P = 0.01). Immunohistochemical staining for XIAP as a novel molecular marker may thus be helpful in the differential diagnosis of thyroid cancer. Moreover, high XIAP expression in conventional PTC is strongly associated with reduced risk of lateral neck lymph node metastasis

Topics: Original Article
Publisher: The Korean Academy of Medical Sciences
OAI identifier: oai:pubmedcentral.nih.gov:3172657
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). A language and environment for statistical computing. Available at http://www.R-project.org [accessed on
  2. (2000). a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell
  3. (2000). Apoptosis in cancer. Carcinogenesis
  4. (2004). Apoptosis signaling in tumor therapy.
  5. (2005). Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease.
  6. (2010). Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine
  7. (2010). BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population.
  8. (2009). BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid
  9. (2002). Cellular longevity: role of apoptosis and replicative senescence. Biogerontology
  10. (2006). Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.
  11. (2006). Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.
  12. (2001). Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res
  13. (2009). Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis.
  14. (2006). Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: a cytomorphologic study of 139 cases with statistical analysis. Cancer
  15. (1998). Fine-needle aspiration of thyroid: an institutional experience. Thyroid
  16. (2008). HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol
  17. (2000). Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell
  18. (2007). Immunohistochemical detection of Xlinked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders. Ann Diagn Pathol
  19. (2006). Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
  20. (2010). Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol
  21. (2008). Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol
  22. (2006). Pathogenetic mechanisms in thyroid follicularcell neoplasia. Nat Rev Cancer
  23. (2009). Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.
  24. (2006). Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology
  25. (2001). the guardian angel. Nat Rev Mol Cell Biol
  26. (2007). The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis
  27. (2003). Why target apoptosis in cancer treatment? Mol Cancer Ther
  28. (2001). XIAP: apoptotic brake and promising therapeutic target. Apoptosis